Riskpilot← Back to searchSign inGet full accessZarkaRa Genomics AB
ABIn liquidationOrg 5561221218Other research and experimental development on natural sciences and engineering · NACE 7219Est. 19680 employees
Revenue 2020
SEK 0
EBITDA margin
—
0% vs 2019
Equity ratio
96.6%
Financial strength
Net profit 2020
SEK -16K
0% vs 2019
| Revenue | SEK 0 | — |
| EBITDA | SEK -16K | +0% |
| Net profit | SEK -16K | +0% |
| Total assets | SEK 446K | -3% |
| Equity | SEK 431K | -4% |
| Employees | 0 | — |
Legal name
ZarkaRa Genomics AB
Org number
5561221218
Legal form
Aktiebolag
NACE code
7219 · Other research and experimental development on natural sciences and engineering
Founded
30 december 1968
Share capital
SEK 0
Employees
0
VAT registered
No
Audit selected
No
Last report
2020-12-31
Financial year
January – December
Company purpose
Bolaget bedriver naturvetenskaplig forskning och utveckling inriktat på jordbruksprodukter inom livsmedelsbranschen.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −943 | −8 | −22 | −16 | −16 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −943 | −8 | −22 | −16 | −16 |
| Net financials | — | — | — | — | — |
| Profit before tax | −943 | −8 | −22 | −16 | −16 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −943 | −8 | −22 | −16 | −16 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|
| Total assets | 508 | 501 | 478 | 462 | 446 |
| Equity | 493 | 486 | 463 | 447 | 431 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 15 | 15 | 15 | 15 | 15 |
| Total debt | 15 | 15 | 15 | 15 | 15 |
EBITDA margin
-1600000.0%
This company
15.8%
Market median
-10126682% vs market
20162020
Equity ratio
96.6%
This company
38.2%
Market median
+153% vs market
20162020
Return on equity
-3.7%
This company
18.4%
Market median
-120% vs market
20162020
Net profit margin
-1600000.0%
This company
8.1%
Market median
-19753186% vs market
20162020
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20162020
Debt / equity
0.03×
This company
0.62×
Market median
+95% vs market
20162020
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
| Name | Role | Member since |
|---|---|---|
| Former (3) | ||
AS Chief Auditor | Chief Auditor | 2021 – 2022 |
ME Audit | Audit | 2021 – 2022 |
JM Liquidator | Liquidator | 2021 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Former (2) | ||
| Board of Directors | 2021 – 2021 | |
| Deputy Board Member | 2021 – 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ZarkaRa Genomics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anna Sofia Götmar Blomstedt | Chief Auditor | 0 companies |
| My Elisabeth Lidén | Audit | 0 companies |
| Johan Mikael Karlsson | Liquidator | 0 companies |
| Per Henrik Porenius | Board of Directors | 0 companies |
| Nils Ola Sven Högberg | Deputy Board Member | 0 companies |